Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colistin loading dose for extensively drug-resistant Acinetobacter baumannii infections
ACTRN12613000862741Phase 4Not yet recruiting
- Sponsor
- Helmi B Sulaiman
- Start
- Aug 2013
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of colistin in Acinetobacter baumannii infection (2 arms), sponsored by Helmi B Sulaiman. Primary endpoint: 30-day mortality rate. Planned start Aug 2013; status: not yet recruiting.
02
Drugs
colistin
03
Conditions
Acinetobacter baumannii infection
Beyond the preview
Go deeper on ACTRN12613000862741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000862741.